A new research paper was published in Oncotarget's Volume 14 on June 19, 2023, entitled, "Utilizing metformin to prevent metabolic syndrome due to androgen deprivation therapy (ADT): a randomized phase II study of metformin in non-diabetic men initiating ADT for advanced prostate cancer."
Metformin's role in preventing metabolic syndrome during androgen deprivation therapy medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.
CHICAGO, IL and FORT WORTH, TX (PRWEB) October 28, 2021 Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced
Share this article
Share this article
SAN DIEGO, Calif. and CALGARY, AB, May 20, 2021 /PRNewswire/ Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) today announced clinical and biomarker data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer. The data will be featured in an upcoming electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, which is taking place virtually from June 4 – 8, 2021.
The newly announced data are from a phase 2 trial evaluating pelareorep in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in pancreatic adenocarcinoma patients who progressed after first-line treatment. Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, which is mediated through the complementary immunotherapeutic effects of the two agents.
Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer Treatment
Financialnewsmedia.com News Commentary
Share this article
Share this article
PALM BEACH, Fla., May 20, 2021 /PRNewswire/ Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so will money flow into R&D efforts to treat this condition. Pancreatic cancer is one of the most dangerous malignancies and is the fourth most common cause of cancer deaths in the U.S. Increasing tobacco consumption, smoking, obesity, and growing awareness pertaining to various treatment options available are propelling the market growth at a global level. The peak incidence of pancreatic cancer is seen in the age group of 65 to 75 years. Thus, growing geriatric population is also expected to drive the growth during the forecast period. Furthermore, pancreatic cancer is ex